BiotechTube

Lutikizumab + Placebo

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Dec 28, 2021 → Dec 1, 2027

NCT ID
NCT05139602

About Lutikizumab + Placebo

Lutikizumab + Placebo is a phase 2 stage product being developed by AbbVie for Hidradenitis Suppurativa. The current trial status is active. This product is registered under clinical trial identifier NCT05139602. Target conditions include Hidradenitis Suppurativa.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT06718101Phase 2Active
NCT06468228Phase 3Recruiting
NCT05139602Phase 2Active

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
LutikizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
MEDI8968 + SalineAstraZenecaPhase 2
52
AnifrolumabAstraZenecaPhase 2
52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85